Rhythm

Pulse Biosciences’ nPulse™ Technology to be Featured at the Heart Rhythm Society 2026 Annual Meeting

Share by Ken Dropiewski on

More in Rhythm:

Share this story

HAYWARD, Calif.–(BUSINESS WIRE)–Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation™ (nsPFA™) energy, today announced that its nPulse™ Cardiac Catheter will be prominently featured during the Heart Rhythm Society (HRS) 2026 Annual Meeting, taking place April 23-26 in Chicago, Illinois. At HRS 2026, Pulse Biosciences will present late‑breaking clinical trial updates, highlighting European feasibility study one‑year outcomes

See full post as originally published on this site

Ken has been in the cardiac, vascular, and interventional space for over 20 years. He is a Partner with McDermott + Bull Executive Search, recognized by Forbes as one of the industry's best with offices across North America and in Europe. Ken is hired by innovative cardiovascular device and biotech companies to help build their best teams possible at the executive level. Prior to search, Ken had an award winning commercial career at Boston Scientific and Johnson & Johnson to include such prestigious awards as President's Club, Ring Club, and Grand Awards. dropiewski@mbexec.com

Leave a Comment

Your email address will not be published. Required fields are marked *

*